Dr. Ryan C. Ramaekers, MD

Dr. Ramaekers practices at Oncology Hematology West in Grand Island, Nebraska.

Dr. Ramaekers' NPI, 1174539936, was assigned on August 1, 2006. Dr. Ramaekers graduated from University of Nebraska College of Medicine in 2003. Dr. Ramaekers holds Nebraska license 23813.

Dr. Ramaekers' primary practice is Oncology Hematology West, at 2730 W Faidley Ave, Grand Island, NE 68803 in Hall County. The practice phone is (402) 354-8124.

Dr. Ramaekers' primary practice is Oncology Hematology West in Grand Island, Nebraska. Dr. Ramaekers is also affiliated with CHI Health St. Francis. The medical group on file is Nebraska Cancer Specialists. Dmand AI also links Dr. Ramaekers to 4 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramaekers practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ramaekers' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Ramaekers' licenses on file in 2 states: Nebraska and Iowa.

CMS data shows 161,080 Medicare services from Dr. Ramaekers across 55 procedure codes in 2024, for 830 Medicare patients. Medicare paid $1,544,931 for them.

CMS counts 830 Medicare patients who saw Dr. Ramaekers in 2024. The largest group is 65 to 74, with 353 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ramaekers' median patient age at 72, with 54% women.

In 2024, Dr. Ramaekers wrote 2,497 Medicare Part D claims for 341 patients. 84% of them were for generic drugs. CMS names the drug for 2,247 of them, across 55 drugs with 11 or more claims each, at $4,340,086 in total drug cost. In 2023, CMS named 1,783 claims across 41 drugs.

Dr. Ramaekers accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ramaekers as offering telehealth.

Dmand AI links 17 papers to Dr. Ramaekers, published from 2015 to 2021. 2015 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Lung Neoplasms. Dr. Ramaekers has published most often in J Clin Oncol. Dr. Ramaekers' most frequent co-authors are Mehmet Sitki Copur, MD, Dron Gauchan, MD and Douglas A. Clark, MD.

Dmand AI links Dr. Ramaekers to 6 clinical trials. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Hodgkin Disease and Multiple Myeloma. National Cancer Institute (NCI) sponsors the most, 2. Open Payments lists research payments to Dr. Ramaekers that name 1 trial.

CMS Open Payments shows 134 general payments to Dr. Ramaekers from 46 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 81% of the total. Janssen Pharmaceuticals, Inc paid the most, $274. It also lists 3 research payments totaling $8,865 from 2020 to 2021, naming 1 clinical trial.

Dr. Ramaekers graduated from University of Nebraska College of Medicine in 2003.